Clinicopathlogical features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan

被引:136
作者
Chiou, C-C [2 ]
Yang, L-C [2 ]
Hung, S-I [3 ]
Chang, Y-C [2 ]
Kuo, T-T [1 ]
Ho, H-C [2 ]
Hu, S. [2 ]
Hong, H-S [2 ]
Chung, W-H [2 ]
机构
[1] Chang Gung Mem Hosp, Dept Pathol, Linkou, Taiwan
[2] Chang Gung Mem Hosp, Dept Dermatol, Linkou, Taiwan
[3] Natl Yang Ming Univ, Sch Med, Inst Pharmacol, Taipei 112, Taiwan
关键词
adverse drug reaction; drug hypersensitivity syndrome; eosinophilia;
D O I
10.1111/j.1468-3083.2008.02585.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Drug rash with eosinophilia and systemic symptoms (DRESS), a group of non-blistering severe cutaneous adverse drug reactions (SCADRs), is characterized by skin rash and multiorgan involvement. Details of this reaction have not been reported in the literature so far. Aim We investigate clinical and pathological features and prognosis of DRESS and hope this study will provide data concerning this disorder in Taiwan. Methods From January 2001 to June 2006, a total of 30 patients, diagnosed with DRESS, were enrolled and evaluated for demographic characteristics, pathological findings, complications and outcome. Results Patient ages ranged from 13 to 78, with an equal sex ratio. The most common offending drug was allopurinol followed by carbamazepine. Pathologic changes observed were lichenoid dermatitis, erythema multiforme, pseudolymphoma and vasculitis. Impairment of liver and renal functions and blood dyscrasia were frequent complications. Active infection or reactivation of HHV-6 was observed in 7 of 11 patients studied serologically. Two patients developed type 1 diabetes mellitus. The mortality rate was 10% (3 of 30). Conclusions DRESS is a heterogeneous group of life-threatening conditions. The leading drug in DRESS in Taiwan is allopurinol. High eosinophil count and multiple underlying diseases are poor prognostic factors in patients with DRESS.
引用
收藏
页码:1044 / 1049
页数:6
相关论文
共 16 条
[1]   ALLOPURINOL HYPERSENSITIVITY SYNDROME - A REVIEW [J].
ARELLANO, F ;
SACRISTAN, JA .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (03) :337-343
[2]   Drug-induced pseudolymphoma and hypersensitivity syndrome - Two different clinical entities [J].
Callot, V ;
Roujeau, JC ;
Bagot, M ;
Wechsler, J ;
Chosidow, O ;
Souteyrand, P ;
Morel, P ;
Dubertret, L ;
Avril, MF ;
Revuz, J .
ARCHIVES OF DERMATOLOGY, 1996, 132 (11) :1315-1321
[3]   THE OUTCOME OF STEVENS-JOHNSON SYNDROME TREATED WITH CORTICOSTEROIDS [J].
CHERIYAN, S ;
PATTERSON, R ;
GREENBERGER, PA ;
GRAMMER, LC ;
LATALL, J .
ALLERGY PROCEEDINGS, 1995, 16 (04) :151-155
[4]   Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection [J].
Chiou, CC ;
Chung, WH ;
Hung, SI ;
Yang, LC ;
Hong, HS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (02) :S14-S17
[5]  
Descamps V, 2001, ARCH DERMATOL, V137, P301
[6]   HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol [J].
Hung, SL ;
Chung, WH ;
Liou, LB ;
Chu, CC ;
Lin, M ;
Huang, HP ;
Lin, YL ;
Lan, JL ;
Yang, LC ;
Hong, HS ;
Chen, MJ ;
Lai, PC ;
Wu, MS ;
Chu, CY ;
Wang, KH ;
Chen, CH ;
Fann, CSJ ;
Wu, JY ;
Chen, YT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (11) :4134-4139
[7]   Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies [J].
Lazarou, J ;
Pomeranz, BH ;
Corey, PN .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (15) :1200-1205
[8]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245
[9]   Clinical heterogeneity of drug hypersensitivity [J].
Roujeau, JC .
TOXICOLOGY, 2005, 209 (02) :123-129
[10]   DRUG-INDUCED TOXIC EPIDERMAL NECROLYSIS .2. CURRENT ASPECTS [J].
ROUJEAU, JC .
CLINICS IN DERMATOLOGY, 1993, 11 (04) :493-500